Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Twist Bioscience

After nearly 10 years, Twist Bioscience spin-off plans Terabyte-scale DNA storage in 2026, intending to store 13TB of data in a 'single drop of water.'

Atlas Data Storage plans terabyte-scale DNA storage by 2026, aiming to store massive data in tiny, highly dense volumes.

Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses

Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses

Twist Bioscience Corporation (NASDAQ:TWST) on Friday posted mixed fourth-quarter results, reporting a loss of 45 cents per share, slightly wider than the consensus estimate of a 43-cent loss.

Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings

Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings

What if a biotech company could flip its financial narrative from loss to profit in just a year? Twist Bioscience Corporation (NASDAQ:TWST) has done just that, reporting a surprising third-quarter income that defied analysts’ expectations

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

First DNA Data Storage Specification Released: First Step Towards Commercialization

The DNA Data Storage Alliance introduced its inaugural specifications for DNA-based data storage this week. This specification outlines a method for encoding essential information within a DNA data archive, crucial for developing and commercializing an interoperable storage ecosystem. DNA data storage uses short strings of deoxyribonucleic acid (DNA) called oligonucleotides…

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

Twist Bioscience Corporation (NASDAQ:TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC:ALPMF) to conduct research activities to identify and optimize proprietary Twist antagonist antibodies. The antibodies will target an undisclosed checkpoint inhibitor pathway in the tumor microenvironment as potential therapeutic development candidates. Ligands in this pathway are…

Twist Bioscience's Earnings: A Preview

Twist Bioscience (NASDAQ:TWST) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Twist Bioscience will report an earnings per share (EPS) of $-1.28.

inkl

Read news from The Economist, FT, and more,
with one subscription

Twist Bioscience Inks Antibody Discovery Pact With MediSix Therapeutics

Twist Bioscience Inks Antibody Discovery Pact With MediSix Therapeutics

Twist Bioscience Corporation (NASDAQ: TWST) and MediSix Therapeutics have collaborated to discover novel antibodies

Twist Bioscience Raises $250M Via Equity Issued At 11% Discount

Twist Bioscience Raises $250M Via Equity Issued At 11% Discount

Twist Bioscience Corporation (NASDAQ: TWST) has priced its upsized underwritten public offering of

Twist Bioscience, Eleven Therapeutics Create Synthetic Viral RNA Molecules To Develop Antiviral Vaccines, Therapeutics

Twist Bioscience, Eleven Therapeutics Create Synthetic Viral RNA Molecules To Develop Antiviral Vaccines, Therapeutics

Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication, antiviral drug screening, and vaccine & therapeutic development.

Twist Bioscience Clocks ~50% Jump In Q1 Sales, Lifts FY22 Revenue Guidance

Twist Bioscience Clocks ~50% Jump In Q1 Sales, Lifts FY22 Revenue Guidance

Twist Bioscience Corp (NASDAQ: TWST) reported a

Recap: Twist Bioscience Q1 Earnings

Recap: Twist Bioscience Q1 Earnings

Twist Bioscience (NASDAQ:TWST) reported its Q1 earnings results on Friday, February 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Earnings Outlook For Twist Bioscience

Earnings Outlook For Twist Bioscience

Twist Bioscience (NASDAQ:TWST) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Twist Bioscience will likely report an Earnings Per Share (EPS) of $-1.06.

Organisations

Western Digital

National Institutes of Health

Astellas Pharma Inc

Quantum Corporation

Tonix Pharmaceuticals

Twist Bioscience

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play